Pomalidomide Triples Survival Time For Treatment Resistant Multiple Myeloma Patients

Standard treatment for multiple myeloma includes drugs such as lenalidomide (LEN) and bortezomib (BORT). However, for patients with lenalidomide and bortezomib resistant multiple myeloma, there are few treatment options. Typically for these patients, high-dose dexamethasone (HiDEX) is commonly used as salvage therapy.

Pomalidomide (POM) is an oral derivative of thalidomide with potent antimyeloma activity. POM works by inhibiting angiogenesis, stromal cell support, and also acts as an immunomodulatory agent.

Recent clinical trial data shows that LEN and BORT resistant patients taking HIDEX had a median overall survival (OS) rate of 7.4 mths while the median OS of patients taking POM plus LoDEX had not been reached at 16 mths. Based on prior clinical data, it is estimated that treatment with POM should triple the survival time of MM patients from approximately 2-3 years to about 7-8 years!

CTOAM Multiple Myeloma and Pomalidomide

Dimopoulos et al., (2012). Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Blood (ASH Annual Meeting Abstracts); 120: Abstract 6.

Speak Your Mind